Page: Quality guidelines-2025/8/6

Document: Feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the feasibility of alternatives to replace titanium dioxide (TiO2) in medicinal products and its possible impact on medicines’ availability-2025/8/6

Document: Annex I - Use of titanium dioxide as excipient in human and veterinary medicines and identification of alternatives - Industry feedback to QWP experts / EMA questions - Final report February 2024-2025/8/6

Page: Clinical investigation of medicines for the treatment of Alzheimer's disease - Scientific guideline-2025/8/6

Document: Concept paper on the need for revision of the guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease-2025/8/6

Document: CHMP-CAT - D80-210 Overview to final EPAR - Rev 07.25 Revamp-2025/8/5

Page: Scientific Advisory Group on Immune and Inflammatory Diseases-2025/8/5

Document: Declaration of interest form: Public call for Scientific Advisory Group on Immune and Inflammatory Diseases-2025/8/5

Document: Public call for expression of interest for experts to become members of the European Medicines Agency's Scientific Advisory Group on Immune and Inflammatory Diseases-2025/8/5

Document: Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 21-24 July 2025-2025/8/5